Pub Date : 2023-10-31DOI: 10.47363/jcrr/2023(5)181
Kangla Tsung
Individualized cancer management is the opposite of the standardized care adapted for current clinical practice by the mainstream medicine. It is not a fancy concept but a logic and inevitable reality derived from the intrinsic characteristics of cancer and host antitumor response. The question is not whether it should be done but how it is done. One missing aspect of individualized management is how to measure its effectiveness. Unlike standardized management that compares therapy efficacy among different management plans by the statistical criteria on the entire groups of patients but not individual patient in the group, individualized management can measure the efficacy on individual patient. This is not only possible, but necessary. A true individualized cancer therapy is not only based on personal situation for each patient, but must also satisfy the criterion that the outcome of selected therapy is predictable for that patient, a feature that current standardized care does not have. Therapy selection based on the individualized assessment of the status of antitumor immunity in each patient is the essential part of individualized management. Thus, treating each patient according to the status of his antitumor immunity should be the most critical skills a physician needs to master when facing each individual cancer patient. In the past seven years, we have been exploring individualized management of cancer through recognizing and manipulating antitumor immunity in each patient. Our combined experiences indicate a significant benefit to patient survival with reduced costs even when such effort was not perfect in the past. With time and more learning, we see this practice becoming more and more practical in a clinical setting. When this individualized approach becomes guideline for cancer management, we will see a significant leap of clinical improvement on both patient survival and cancer cure rate
{"title":"Efficacy of Individualized Cancer Management","authors":"Kangla Tsung","doi":"10.47363/jcrr/2023(5)181","DOIUrl":"https://doi.org/10.47363/jcrr/2023(5)181","url":null,"abstract":"Individualized cancer management is the opposite of the standardized care adapted for current clinical practice by the mainstream medicine. It is not a fancy concept but a logic and inevitable reality derived from the intrinsic characteristics of cancer and host antitumor response. The question is not whether it should be done but how it is done. One missing aspect of individualized management is how to measure its effectiveness. Unlike standardized management that compares therapy efficacy among different management plans by the statistical criteria on the entire groups of patients but not individual patient in the group, individualized management can measure the efficacy on individual patient. This is not only possible, but necessary. A true individualized cancer therapy is not only based on personal situation for each patient, but must also satisfy the criterion that the outcome of selected therapy is predictable for that patient, a feature that current standardized care does not have. Therapy selection based on the individualized assessment of the status of antitumor immunity in each patient is the essential part of individualized management. Thus, treating each patient according to the status of his antitumor immunity should be the most critical skills a physician needs to master when facing each individual cancer patient. In the past seven years, we have been exploring individualized management of cancer through recognizing and manipulating antitumor immunity in each patient. Our combined experiences indicate a significant benefit to patient survival with reduced costs even when such effort was not perfect in the past. With time and more learning, we see this practice becoming more and more practical in a clinical setting. When this individualized approach becomes guideline for cancer management, we will see a significant leap of clinical improvement on both patient survival and cancer cure rate","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139309348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-31DOI: 10.47363/jcrr/2023(5)180
Annu Kumari
Hepatocellular carcinoma (HCC), a widely prevalent form of liver malignancy, is a leading contributor to cancer-related mortality globally, despite advances in preventive and diagnostic technologies. It is closely associated with cirrhosis, with major contributions from hepatitis B and C infections and alcohol consumption. Early detection of HCC is crucial as it is often diagnosed at an asymptomatic stage. Radiological screenings and serological markers are effective methods of achieving early detection. Various surgical methods, including liver transplantation, and therapies such as radiofrequency lesioning and chemoembolization, are employed to treat this disease. However, due to limited donor availability and late diagnosis, treatment can be delayed. Tumour size, liver disease severity, and patient’s overall health are among the factors that influence the disease. Nanotechnology, a field that involves the precise manipulation of materials at the nanometer scale and the targeted delivery of therapeutic agents, presents a promising solution for HCC therapy. The utilization of nanoparticle-based therapies allows for the specific targeting of tumour-associated antigens, which enhances drug delivery and reduces drug-induced toxicity. Furthermore, nanomaterials such as carbon nanoparticles and biochemical sensors aid in the detection of oncological markers. Nanomedicine-based approaches possess the potential to revolutionize HCC therapy by improving drug delivery and targeting liver cancer stem cells. Specifically, targeted ligand-mediated therapy using saccharide or polysaccharide compounds, antibodies, peptides, and aptamers shows promise for liver-specific HCC treatment. Additionally, nanotherapy aimed at liver cancer stem cells (LCSCs) provides new possibilities to overcome the limitations of conventional treatments and improve patient outcomes. Ultimately, nanotechnology-based approaches hold great potential in enhancing the effectiveness of HCC therapy and offer new avenues for precision medicine in cancer treatment.
{"title":"Navigating the Future: Nanotechnological Strategies for Tackling Hepatocellular Carcinoma","authors":"Annu Kumari","doi":"10.47363/jcrr/2023(5)180","DOIUrl":"https://doi.org/10.47363/jcrr/2023(5)180","url":null,"abstract":"Hepatocellular carcinoma (HCC), a widely prevalent form of liver malignancy, is a leading contributor to cancer-related mortality globally, despite advances in preventive and diagnostic technologies. It is closely associated with cirrhosis, with major contributions from hepatitis B and C infections and alcohol consumption. Early detection of HCC is crucial as it is often diagnosed at an asymptomatic stage. Radiological screenings and serological markers are effective methods of achieving early detection. Various surgical methods, including liver transplantation, and therapies such as radiofrequency lesioning and chemoembolization, are employed to treat this disease. However, due to limited donor availability and late diagnosis, treatment can be delayed. Tumour size, liver disease severity, and patient’s overall health are among the factors that influence the disease. Nanotechnology, a field that involves the precise manipulation of materials at the nanometer scale and the targeted delivery of therapeutic agents, presents a promising solution for HCC therapy. The utilization of nanoparticle-based therapies allows for the specific targeting of tumour-associated antigens, which enhances drug delivery and reduces drug-induced toxicity. Furthermore, nanomaterials such as carbon nanoparticles and biochemical sensors aid in the detection of oncological markers. Nanomedicine-based approaches possess the potential to revolutionize HCC therapy by improving drug delivery and targeting liver cancer stem cells. Specifically, targeted ligand-mediated therapy using saccharide or polysaccharide compounds, antibodies, peptides, and aptamers shows promise for liver-specific HCC treatment. Additionally, nanotherapy aimed at liver cancer stem cells (LCSCs) provides new possibilities to overcome the limitations of conventional treatments and improve patient outcomes. Ultimately, nanotechnology-based approaches hold great potential in enhancing the effectiveness of HCC therapy and offer new avenues for precision medicine in cancer treatment.","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139308147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-31DOI: 10.47363/jcrr/2023(5)177
M. Hunis, A. Hunis
Metastatic tumors of unknown primary (MUOs) present a diagnostic challenge due to the absence of an identifiable primary tumor site. The diagnostic approach for MUOs involves a comprehensive evaluation that includes clinical assessment, imaging studies, laboratory tests, and tissue sampling. Various imaging modalities, such as CT, MRI, PET scans, and ultrasound, are used to assess the extent of metastasis and identify potential primary tumor sites. Treatment options for MUOs include systemic therapies like chemotherapy, targeted therapy, immunotherapy, and hormone therapy, along with supportive care measures. Prognosis varies widely and is influenced by factors such as the extent of metastasis, tumor characteristics, treatment response, and patient factors [1]. Artificial intelligence (AI) has the potential to aid in diagnosis and management through image analysis, predictive modeling, pathology analysis, and risk assessment. The integration of AI requires careful validation and collaboration between healthcare professionals and AI experts. A multidisciplinary approach is crucial for optimal management of MUOs, and ongoing research aims to enhance diagnostic methods, treatment strategies, and prognostic models.
{"title":"Metastatic Tumors of Unknown Primary (Muos) Definition, Frequency and General Considerations","authors":"M. Hunis, A. Hunis","doi":"10.47363/jcrr/2023(5)177","DOIUrl":"https://doi.org/10.47363/jcrr/2023(5)177","url":null,"abstract":"Metastatic tumors of unknown primary (MUOs) present a diagnostic challenge due to the absence of an identifiable primary tumor site. The diagnostic approach for MUOs involves a comprehensive evaluation that includes clinical assessment, imaging studies, laboratory tests, and tissue sampling. Various imaging modalities, such as CT, MRI, PET scans, and ultrasound, are used to assess the extent of metastasis and identify potential primary tumor sites. Treatment options for MUOs include systemic therapies like chemotherapy, targeted therapy, immunotherapy, and hormone therapy, along with supportive care measures. Prognosis varies widely and is influenced by factors such as the extent of metastasis, tumor characteristics, treatment response, and patient factors [1]. Artificial intelligence (AI) has the potential to aid in diagnosis and management through image analysis, predictive modeling, pathology analysis, and risk assessment. The integration of AI requires careful validation and collaboration between healthcare professionals and AI experts. A multidisciplinary approach is crucial for optimal management of MUOs, and ongoing research aims to enhance diagnostic methods, treatment strategies, and prognostic models.","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"75 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127164438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.47363/jcrr/2023(5)172
Rashmi Methry
Acute myeloid leukemia (AML) is a hematopoietic stem cell disorder characterized by a block in differentiation of hematopoiesis, resulting in growth of a clonal population of neoplastic cells or blasts. Chemotherapeutics leads to side effects. To minimize potential toxicities and to maximize the optimal quality of life, nurse can assist the patient by providing instructions and making the care provider equipped with knowledge. The aim of the study was to assess the knowledge regarding chemotherapy, its side effects and its management in patients with AML and to assess the effect of structured teaching programme in experimental and control group. Quantitative, quasi-experimental pretest posttest control group design study was done It was found that there is significant improvement in posttest knowledge score in experimental group (P value -0.000) and number of participants correctly answered to the items in questionnaire increased after the structured teaching program in experimental group.
{"title":"A Study to Assess the Effect of Structured Teaching Programme on Knowledge of Patients with Acute Myeloid Leukaemia on Chemotherapy Schedule, Side Effects and its Management at a Tertiary Cancer Centre","authors":"Rashmi Methry","doi":"10.47363/jcrr/2023(5)172","DOIUrl":"https://doi.org/10.47363/jcrr/2023(5)172","url":null,"abstract":"Acute myeloid leukemia (AML) is a hematopoietic stem cell disorder characterized by a block in differentiation of hematopoiesis, resulting in growth of a clonal population of neoplastic cells or blasts. Chemotherapeutics leads to side effects. To minimize potential toxicities and to maximize the optimal quality of life, nurse can assist the patient by providing instructions and making the care provider equipped with knowledge. The aim of the study was to assess the knowledge regarding chemotherapy, its side effects and its management in patients with AML and to assess the effect of structured teaching programme in experimental and control group. Quantitative, quasi-experimental pretest posttest control group design study was done It was found that there is significant improvement in posttest knowledge score in experimental group (P value -0.000) and number of participants correctly answered to the items in questionnaire increased after the structured teaching program in experimental group.","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114508584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.47363/jcrr/2023(5)175
A. Hunis
{"title":"Public Policies on Cancer","authors":"A. Hunis","doi":"10.47363/jcrr/2023(5)175","DOIUrl":"https://doi.org/10.47363/jcrr/2023(5)175","url":null,"abstract":"","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116686094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.47363/jcrr/2023(5)173
Quader Naseer
Phyllodes tumours are rare breast tumours that represent less than 1% of all breast tumours. They can be classified into three categories based on their histological features: benign, borderline, and malignant. Malignant phyllodes tumours are the most aggressive and can metastasize to distant organs. Here we report a case of a 26-year-old female with a malignant phyllodes tumour of the breast. The patient underwent wide local excision followed by adjuvant radiotherapy. We discuss the diagnostic and therapeutic challenges of managing this rare malignancy.
{"title":"A Rare Case of Malignant Phyllodes Tumor in a Young Female","authors":"Quader Naseer","doi":"10.47363/jcrr/2023(5)173","DOIUrl":"https://doi.org/10.47363/jcrr/2023(5)173","url":null,"abstract":"Phyllodes tumours are rare breast tumours that represent less than 1% of all breast tumours. They can be classified into three categories based on their histological features: benign, borderline, and malignant. Malignant phyllodes tumours are the most aggressive and can metastasize to distant organs. Here we report a case of a 26-year-old female with a malignant phyllodes tumour of the breast. The patient underwent wide local excision followed by adjuvant radiotherapy. We discuss the diagnostic and therapeutic challenges of managing this rare malignancy.","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"121 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130542703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.47363/jcrr/2023(5)176
Eric B. Berg, G. Tenenbaum, Maurice Israel
Cancer cells harness a mechanism known as ketolysis to generate energy, a process that involves the enzymes SCOT and ACAT1, instrumental in the creation of a crucial molecule named acetyl-CoA. This molecule plays a vital role in cellular energy production. Interestingly, cancer cells are capable of alternative methods for generating acetyl-CoA, such as the incorporation of external acetate. Although restraining the function of SCOT and ACAT1 may decelerate cancerous growth, it could potentially impede the tumor cells’ ability to produce necessary new membranes for their survival.
{"title":"Unraveling the Cancer Metabolism: Fasting Reset, Ketogenic Diet? and Therapeutic Strategies","authors":"Eric B. Berg, G. Tenenbaum, Maurice Israel","doi":"10.47363/jcrr/2023(5)176","DOIUrl":"https://doi.org/10.47363/jcrr/2023(5)176","url":null,"abstract":"Cancer cells harness a mechanism known as ketolysis to generate energy, a process that involves the enzymes SCOT and ACAT1, instrumental in the creation of a crucial molecule named acetyl-CoA. This molecule plays a vital role in cellular energy production. Interestingly, cancer cells are capable of alternative methods for generating acetyl-CoA, such as the incorporation of external acetate. Although restraining the function of SCOT and ACAT1 may decelerate cancerous growth, it could potentially impede the tumor cells’ ability to produce necessary new membranes for their survival.","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116273270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-31DOI: 10.47363/jcrr/2022(4)168
Namratha Sai Reddy B, N. Vaddeboina
Synchronous dual primary cancers have been reported in the past while majority of these are sporadic only few are hereditary. There have been a couple of case reports of synchronous primary ovarian cancer and renal cell carcinoma (RCC) and the first reported case was in 1988 by Myoga et al. Currently there is no clear explanation about synchronous RCC and ovarian cancers but steroid hormones & its receptors are thought to play a role. It is important for the clinician and the pathologist to rule out the possibility of metastatic deposits for the better management of the disease. Here we report a rare presentation of dual synchronous primaries of Clear cell RCC and High grade serous ovarian cancer in a 48year old female.
{"title":"Synchronous Serous Carcinoma of Ovary and Clear Cell Carcinoma of Kidney","authors":"Namratha Sai Reddy B, N. Vaddeboina","doi":"10.47363/jcrr/2022(4)168","DOIUrl":"https://doi.org/10.47363/jcrr/2022(4)168","url":null,"abstract":"Synchronous dual primary cancers have been reported in the past while majority of these are sporadic only few are hereditary. There have been a couple of case reports of synchronous primary ovarian cancer and renal cell carcinoma (RCC) and the first reported case was in 1988 by Myoga et al. Currently there is no clear explanation about synchronous RCC and ovarian cancers but steroid hormones & its receptors are thought to play a role. It is important for the clinician and the pathologist to rule out the possibility of metastatic deposits for the better management of the disease. Here we report a rare presentation of dual synchronous primaries of Clear cell RCC and High grade serous ovarian cancer in a 48year old female.","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114575674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-31DOI: 10.47363/jcrr/2022(4)169
A. Mohammed, H. Bakhribah, R. Tulbah
Bronchogenic carcinoma is a leading cause of cancer mortality worldwide. Of lung cancer cases overall, 50% have metastasis at presentation, mostly to the brain, bone, liver, the adrenal glands ,thoracic cavity and non-regional lymph nodes .This case report presents a female patient with three rare sites of lung cancer metastasis: breast, colon, and skin. Her initial presentation was a several-month history of a mass in the left breast and in the upper abdominal wall, dyspepsia, weight loss, and intermittent per rectal bleeding. Diagnosis of this case was difficult because of the challenge to differentiate between primary breast cancer and metastasis. However, the diagnosis was made by the interpretation of images and immunohistochemistry.
{"title":"Non-Small Cell Lung Cancer Metastases to Breast, Colon and Skin: A Case Report","authors":"A. Mohammed, H. Bakhribah, R. Tulbah","doi":"10.47363/jcrr/2022(4)169","DOIUrl":"https://doi.org/10.47363/jcrr/2022(4)169","url":null,"abstract":"Bronchogenic carcinoma is a leading cause of cancer mortality worldwide. Of lung cancer cases overall, 50% have metastasis at presentation, mostly to the brain, bone, liver, the adrenal glands ,thoracic cavity and non-regional lymph nodes .This case report presents a female patient with three rare sites of lung cancer metastasis: breast, colon, and skin. Her initial presentation was a several-month history of a mass in the left breast and in the upper abdominal wall, dyspepsia, weight loss, and intermittent per rectal bleeding. Diagnosis of this case was difficult because of the challenge to differentiate between primary breast cancer and metastasis. However, the diagnosis was made by the interpretation of images and immunohistochemistry.","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125515076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-30DOI: 10.47363/jcrr/2022(4)165
A. H. Khan
This abstract attempts to explore if psychosomatic illnesses are genetic in origin. The word psychosomatic comes from two roots: psycho meaning mind and somatic meaning body. The symptoms of psychosomatic illnesses are caused by emotional stress rather than an organic, physical source in the body. Our mind is outside of our brain and cannot be studied, but we can study its effect our body. To ensure if the psychosomatic illnesses have any association with our body and to identify the root cause of these illnesses in our body if any, we sequenced the human genome that is we read the entire book of our life. Our genome provides the total genetic information that make us humans. It carries the greatest catalog of human genes on planet Earth. Our genome consists of 46 volumes of encyclopedia called chromosomes which carry 24,000 chapters called genes. Of all genes in our genome, 16,000 are good genes, 6,000 bad (or mutated) genes responsible for causing six thousand different diseases and 2,000 pseudogenes which have lost their functions. Out of 6,000 variants, not a single mutated gene is linked to any symptom of psychosomatic disorders such as stress, hypertension, respiratory ailments, gastrointestinal disturbances, migraine, tension, headaches, pelvic pain, impotence, frigidity, dermatitis, ulcers. stress and anxiety. We examine the association of any of these psychosomatic symptoms with any of those six thousand mutated genes in our genome, we found no correlation with genetic diseases. We conclude that psychosomatic illnesses are not organic in nature and cannot be treated with organic molecules.
{"title":"The Impact of Sequencing Human Genome on the Psychosomatic Illnesses","authors":"A. H. Khan","doi":"10.47363/jcrr/2022(4)165","DOIUrl":"https://doi.org/10.47363/jcrr/2022(4)165","url":null,"abstract":"This abstract attempts to explore if psychosomatic illnesses are genetic in origin. The word psychosomatic comes from two roots: psycho meaning mind and somatic meaning body. The symptoms of psychosomatic illnesses are caused by emotional stress rather than an organic, physical source in the body. Our mind is outside of our brain and cannot be studied, but we can study its effect our body. To ensure if the psychosomatic illnesses have any association with our body and to identify the root cause of these illnesses in our body if any, we sequenced the human genome that is we read the entire book of our life. Our genome provides the total genetic information that make us humans. It carries the greatest catalog of human genes on planet Earth. Our genome consists of 46 volumes of encyclopedia called chromosomes which carry 24,000 chapters called genes. Of all genes in our genome, 16,000 are good genes, 6,000 bad (or mutated) genes responsible for causing six thousand different diseases and 2,000 pseudogenes which have lost their functions. Out of 6,000 variants, not a single mutated gene is linked to any symptom of psychosomatic disorders such as stress, hypertension, respiratory ailments, gastrointestinal disturbances, migraine, tension, headaches, pelvic pain, impotence, frigidity, dermatitis, ulcers. stress and anxiety. We examine the association of any of these psychosomatic symptoms with any of those six thousand mutated genes in our genome, we found no correlation with genetic diseases. We conclude that psychosomatic illnesses are not organic in nature and cannot be treated with organic molecules.","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"172 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129521199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：